Search

everythinglearnresearchcommunity

for

Search:↓

The study found a link between the severity of Lichen Planopilaris seen by doctors and the details seen under a microscope, and created a new way to measure this severity.

Centralized imaging provides more accurate and consistent hair loss measurements in alopecia areata.

Alopecia areata severity is influenced by factors like long disease duration, relapses, treatment response, and mental health, leading to the creation of a new severity measurement tool.

The treatment increased hair follicle counts and is potentially effective for male hair loss without serious side effects.

The Brigham Eyelash Tool for Alopecia (BELA) is a reliable way to measure eyelash loss in alopecia areata patients.

ALRV5XR effectively increases hair density in men with androgenetic alopecia without adverse effects.

Blocking allopregnanolone production in mice makes them more anxious after stress, but this can be reversed with a drug that mimics allopregnanolone.

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.

Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.

Changes in hair follicle structure may help diagnose and monitor alopecia.

Using single dermal papillae is unreliable for analyzing androgen metabolism in hair follicles.

Isoallopregnanolone may be a safe and effective treatment for reducing tics in a mouse model of Tourette syndrome.

The new tool helps measure the impact of alopecia areata on children's quality of life.

Pix Liquida may help treat alopecia areata.

A new method accurately measures clobetasol propionate in hair and skin.

Patients and doctors often disagree on alopecia areata severity and treatment satisfaction.

The 12-point scale is better for evaluating small changes in hair condition after using hair care products.

Allopregnanolone affects fear responses differently in male and female rats, possibly explaining sex differences in anxiety disorders.

Alopecia affects patients' quality of life, with younger patients and longer-lasting hair loss experiencing greater impact.

Both treatments improved alopecia areata, but methotrexate caused more skin darkening, while triamcinolone caused skin lightening and thinning.

3α-AdiolG is a good marker for androgen activity in women with excessive hair growth and decreases with anti-androgen treatment.

Paroxetine relieves pain by increasing allopregnanolone levels.

Most adults with alopecia have some quality of life impairment, mainly minimal to moderate, and are treated with minoxidil.

A new classification and scoring system is needed for alopecia areata to better assess severity.

The Progressive Loss Risk Scale is a system that shows the long-term risks of hair restoration surgery, which can change based on factors like age and transplant area.